This is a non-binding exploratory MOU with no financial terms, unlikely to move the stock near-term. The key catalyst for TLX remains the PDUFA date of September 11, 2026 for TLX101-Px. Monitor for any subsequent definitive agreements or expansion announcements.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $9.16entry
- T+1 · 6mo ago −4.26%α −3.54% · $8.77
- T+5 · 5mo ago +2.73%α +5.69% · $9.41
- T+20 · 5mo ago +29.26%α +30.82% · $11.84
- T+60 · 3mo ago +21.51%α +20.39% · $11.13
Price Chart
How similar events traded
Executive Summary
Telix Pharmaceuticals and United Imaging signed an MOU to evaluate a strategic research collaboration integrating Telix's radiopharmaceuticals with United Imaging's scanner platforms, initially focusing on TLX101-Px (Pixclara) in the U.S. The collaboration is exploratory and non-binding, with no financial terms disclosed, and does not change Telix's near-term revenue or regulatory trajectory.
Key Facts
- MOU signed with United Imaging Healthcare North America to evaluate integrated theranostics workflows.
- Initial focus on TLX101-Px (Pixclara, Floretyrosine F 18) in the U.S., with potential expansion to other products and markets.
- TLX101-Px NDA accepted by FDA in April 2026, with PDUFA goal date of September 11, 2026.
- No financial terms, revenue commitments, or binding obligations disclosed.
- Collaboration includes scanning protocol optimization, workflow tools, and pilot programs.
Financial Impact
No financial terms disclosed; collaboration is exploratory and non-binding.
Risk Factors
- MOU is non-binding and may not lead to a definitive agreement.
- TLX101-Px has not received marketing authorization in any jurisdiction; FDA decision pending.
- No revenue or cost-sharing details provided; financial impact uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304988 |
Track record
27 reports on TLX
10 of 21 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 19 of 21 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers